Results 1 to 10 of about 198,741 (309)

Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders

BMC Women's Health, 2021
Background Consequences of long-term B cell depletion with rituximab are not well understood. We describe inflammatory vaginitis as a potential side effect of long-term rituximab treatment, distinct from previously described vulvovaginal pyoderma ...
Laura Yockey, Sarah Dowst, Reza Zonozi, Noah Huizenga, Patrick Murphy, Karen Laliberte, Jillian Rosenthal, John L. Niles, Caroline M. Mitchell   +8 more
doaj   +1 more source

Diagnostic delays in vasculitis and factors associated with time to diagnosis

Orphanet Journal of Rare Diseases, 2021
Background Patients with vasculitis, a set of rare diseases, encounter delays in obtaining an accurate diagnosis which can lead to substantial morbidity and increased mortality.
Antoine G. Sreih, Keri Cronin, Dianne G. Shaw, Kalen Young, Cristina Burroughs, Joyce Kullman, Kirthi Machireddy, Carol A. McAlear, Peter A. Merkel, for the Vasculitis Patient-Powered Research Network   +9 more
doaj   +1 more source

Reuma.pt/vasculitis – the Portuguese vasculitis registry [PDF]

Orphanet Journal of Rare Diseases, 2020
AbstractBackgroundThe vasculitides are a group of rare diseases with different manifestations and outcomes. New therapeutic options have led to the need for long-term registries. The Rheumatic Diseases Portuguese Register, Reuma.pt, is a web-based electronic clinical record, created in 2008, which currently includes specific modules for 12 diseases and 
Ponte, Cristina, Khmelinskii, Nikita, Teixeira, Vítor, Luz, Karine, Peixoto, Daniela, Rodrigues, Marília, Luís, Mariana, Teixeira, Lídia, Sousa, Sandra, Madeira, Nathalie, Aleixo, Joana A., Pedrosa, Teresa, Serra, Sofia, Campanilho-Marques, Raquel, Castelão, Walter, Cordeiro, Ana, Cordeiro, Inês, Fernandes, Sílvia, Macieira, Carla, Madureira, Pedro, Malcata, Armando, Vieira, Romana, Martins, Fernando, Sequeira, Graça, Branco, Jaime C., Costa, Lúcia, Patto, José Vaz, da Silva, José Canas, Pereira da Silva, José A., Afonso, Carmo, Canhao, Helena, Santos, Maria, Luqmani, Raashid A., Fonseca, João Eurico   +33 more
openaire   +5 more sources

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Trials, 2023
Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms.
Mark E. McClure, Seerapani Gopaluni, James Wason, Robert B. Henderson, Andre Van Maurik, Caroline C.O. Savage, Charles D. Pusey, Alan D. Salama, Paul A. Lyons, Jacinta Lee, Kim Mynard, David R. Jayne, Rachel B. Jones, on behalf the COMBIVAS investigators   +13 more
doaj   +1 more source

Introduction to the PANLAR Guidelines: Giant Cell Arteritis

Global Rheumatology, 2022
Introduction to the PANLAR Guidelines: Giant Cell Arteritis Dr. Sebastián Unizony describes how the process of construction and consolidation of this document by a team of experts was.
Sebastian Unizony
doaj   +1 more source

Patient involvement in medical research: what patients and physicians learn from each other

Orphanet Journal of Rare Diseases, 2019
Background There is increasing interest in actively involving patients in the process of medical research to help ensure research is relevant and important to both researchers and people affected by the disease under study.
Kalen Young, Dana Kaminstein, Ana Olivos, Cristina Burroughs, Celeste Castillo-Lee, Joyce Kullman, Carol McAlear, Dianne G. Shaw, Antoine Sreih, George Casey, Vasculitis Patient-Powered Research Network, Peter A. Merkel   +11 more
doaj   +1 more source

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis

RMD Open, 2019
Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, clinical features and treatment responses.
David Jayne, Rachel B Jones, Vítor Teixeira, Aladdin J Mohammad, Rona Smith   +4 more
doaj   +1 more source

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease

Frontiers in Immunology, 2021
ObjectiveTo evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement therapy.MethodsPatients ...
Joanna Tieu, Joanna Tieu, Joanna Tieu, Rona M. Smith, Rona M. Smith, Seerapani Gopaluni, Seerapani Gopaluni, Dinakantha S. Kumararatne, Mark McClure, Mark McClure, Ania Manson, Sally Houghton, David R. W. Jayne, David R. W. Jayne   +13 more
doaj   +1 more source

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients

Frontiers in Immunology, 2020
BackgroundB-cell depletion with rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients.
Laura S. van Dam, Jelle M. Oskam, Sylvia W. A. Kamerling, Eline J. Arends, O. W. Bredewold, Magdalena A. Berkowska, Jacques J. M. van Dongen, Ton J. Rabelink, Cees van Kooten, Y. K. Onno Teng   +9 more
doaj   +1 more source

Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial

Trials, 2022
Background Belimumab, an anti-B-cell activating factor antibody, is approved for the treatment of auto-antibody positive systemic lupus erythematosus with a high degree of disease activity.
Mieke van Schaik, Eline J. Arends, Darius Soonawala, Ellen van Ommen, Karina de Leeuw, Maarten Limper, Pieter van Paassen, Tom W. J. Huizinga, René E. M. Toes, Cees van Kooten, Joris I. Rotmans, Ton J. Rabelink, Y. K. Onno Teng   +12 more
doaj   +1 more source